Literature DB >> 25085000

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.

Manja Idorn1, Tania Køllgaard, Per Kongsted, Lisa Sengeløv, Per Thor Straten.   

Abstract

Myeloid-derived suppressor cells (MDSC) are believed to play a role in immune suppression and subsequent failure of T cells to mount an efficient anti-tumor response, by employing both direct T-cell inhibition as well as induction of regulatory T cells (Tregs). Investigating the frequency and function of immune suppressive cell subsets in the peripheral blood of 41 patients with prostate cancer (PC) and 36 healthy donors (HD) showed a significant increase in circulating CD14(+) HLA-DR(low/neg) monocytic MDSC (M-MDSC) and Tregs in patients with PC compared to HD. Furthermore, M-MDSC frequencies correlated positively with Treg levels. In vitro proliferation assay with autologous T cells confirmed M-MDSC-mediated T-cell suppression, and intracellular staining of immune suppressive enzyme iNOS revealed a higher expression in M-MDSC from patients with PC. Increased frequencies of M-MDSC correlated with known negative prognostic markers in patients with PC including elevated levels of lactate dehydrogenase and prostate-specific antigen. Accordingly, high levels of M-MDSC were associated with a shorter median overall survival. Our data strongly suggest that M-MDSC, possibly along with Tregs, play a role in establishing an immune suppressive environment in patients with PC. Moreover, correlation of M-MDSC frequency with known prognostic markers and the observed impact on OS could reflect a possible role in tumor progression. Further insight into the generation and function of MDSC and their interplay with Tregs and other cell types may suggest ways to tackle their induction and/or function to improve immunological tumor control.

Entities:  

Mesh:

Year:  2014        PMID: 25085000     DOI: 10.1007/s00262-014-1591-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  72 in total

1.  Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.

Authors:  Gregory B Lesinski; Patrick K Reville; Thomas A Mace; Gregory S Young; Jennifer Ahn-Jarvis; Jennifer Thomas-Ahner; Yael Vodovotz; Zeenath Ameen; Elizabeth Grainger; Kenneth Riedl; Steven Schwartz; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

Review 2.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 3.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cancer Immunol Immunother       Date:  2016-02-24       Impact factor: 6.968

4.  Granulocytic myeloid-derived suppressor cells from human cord blood modulate T-helper cell response towards an anti-inflammatory phenotype.

Authors:  Natascha Köstlin; Margit Vogelmann; Bärbel Spring; Julian Schwarz; Judith Feucht; Christoph Härtel; Thorsten W Orlikowsky; Christian F Poets; Christian Gille
Journal:  Immunology       Date:  2017-06-08       Impact factor: 7.397

Review 5.  Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.

Authors:  Anca Dorhoi; Leigh A Kotzé; Jay A Berzofsky; Yongjun Sui; Dmitry I Gabrilovich; Ankita Garg; Richard Hafner; Shabaana A Khader; Ulrich E Schaible; Stefan He Kaufmann; Gerhard Walzl; Manfred B Lutz; Robert N Mahon; Suzanne Ostrand-Rosenberg; William Bishai; Nelita du Plessis
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

6.  Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.

Authors:  Hui-Ming Chen; Ge Ma; Neil Gildener-Leapman; Samuel Eisenstein; Brian A Coakley; Junko Ozao; John Mandeli; Celia Divino; Myron Schwartz; Max Sung; Robert Ferris; Johnny Kao; Lu-Hai Wang; Ping-Ying Pan; Eric C Ko; Shu-Hsia Chen
Journal:  Clin Cancer Res       Date:  2015-04-28       Impact factor: 12.531

Review 7.  A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.

Authors:  Christopher Shipp; Lisa Speigl; Nicole Janssen; Alexander Martens; Graham Pawelec
Journal:  Cell Mol Life Sci       Date:  2016-05-28       Impact factor: 9.261

Review 8.  Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.

Authors:  Michelle N Messmer; Colleen S Netherby; Debarati Banik; Scott I Abrams
Journal:  Cancer Immunol Immunother       Date:  2014-11-29       Impact factor: 6.968

9.  MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.

Authors:  Eleftheria A Anastasopoulou; Ioannis F Voutsas; Michael Papamichail; Constantin N Baxevanis; Sonia A Perez
Journal:  Oncoimmunology       Date:  2016-05-02       Impact factor: 8.110

10.  Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.

Authors:  Jill M Hamilton-Reeves; Misty D Bechtel; Lauren K Hand; Amy Schleper; Thomas M Yankee; Prabhakar Chalise; Eugene K Lee; Moben Mirza; Hadley Wyre; Joshua Griffin; Jeffrey M Holzbeierlein
Journal:  Eur Urol       Date:  2015-11-30       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.